Effect of 40 mg versus 10 mg of atorvastatin on oxidized low-density lipoprotein, high-sensitivity c-reactive protein, circulating endothelial-derived microparticles, and endothelial progenitor cells in patients with ischemic cardiomyopathy

Clinical Cardiology

Volumn 35, Issue 2, 2012, Pages 125-130

  Huang, Bingsheng ^a,b   Cheng, Ying ^a   Xie, Qiang ^a   Lin, Guixiong ^a   Wu, Yuyan ^a   Feng, Yanling ^a   Gao, Jinxiong ^a   Xu, Dingli ^a,b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFECT; ENDOTHELIAL PROGENITOR CELL; FEMALE; FOLLOW UP; HUMAN; ISCHEMIC CARDIOMYOPATHY; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEMBRANE MICROPARTICLE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOMYOPATHIES; CELL-DERIVED MICROPARTICLES; ECHOCARDIOGRAPHY; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; HEPTANOIC ACIDS; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PYRROLES; STEM CELLS;

EID: 84862806148     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.21017     Document Type: Article

References (36)

1. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 1999; 85: 221-228. (Pubitemid 29377293)
2. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997; 275: 964-967. (Pubitemid 27087709)
3. Bhattacharya V, McSweeney PA, Shi Q, et al. Enhanced endothelialization and microvessel formation in polyester grafts seeded with CD34(+) bone marrow cells. Blood. 2000; 95: 581-585. (Pubitemid 30041673)
4. Gehling UM, Ergun S, Schumacher U, et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood. 2000; 95: 3106-3112. (Pubitemid 30321161)
5. Crosby JR, Kaminski WE, Schatteman G, et al. Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Circ Res. 2000; 87: 728-730.
6. Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001; 89: E1-E7.
7. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003; 348: 593-600. (Pubitemid 36204953)
8. Schmidt-Lucke C, Rossig L, Fichtlscherer S, et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation. 2005; 111: 2981-2987. (Pubitemid 40814192)
9. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005; 353: 999-1007. (Pubitemid 41262334)
10. Valgimigli M, Rigolin GM, Fucili A, et al. CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure. Circulation. 2004; 110: 1209-1212. (Pubitemid 39202334)
11. Kissel CK, Lehmann R, Assmus B, et al. Selective functional exhaustion of hematopoietic progenitor cells in the bone marrow of patients with postinfarction heart failure. J Am Coll Cardiol. 2007; 49: 2341-2349. (Pubitemid 46891715)
12. Lacroix R, Sabatier F, Mialhe A, et al. Activation of plasminogen into plasmin at the surface of endothelial microparticles: a mechanism that modulates angiogenic properties of endothelial progenitor cells in vitro. Blood. 2007; 110: 2432-2439. (Pubitemid 47523164)
13. Curtis AM, Zhang L, Medenilla E, et al. Relationship of microparticles to progenitor cells as a measure of vascular health in a diabetic population. Cytometry B Clin Cytom. 2010;78: 329-337.
14. Tramontano AF, O'Leary J, Black AD, et al. Statin decreases endothelial microparticle release from human coronary artery endothelial cells: implication for the Rho-kinase pathway. Biochem Biophys Res Commun. 2004; 320: 34-38. (Pubitemid 38781781)
15. Inzhutova AI, Larionov AA, Petrova MM, et al. Stabilization of cellular membranes as a target of vascular therapy [in Russian]. Kardiologiia. 2011;51: 52-55.
16. Itabe H, Yamamoto H, Imanaka T, et al. Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J Lipid Res. 1996; 37: 45-53. (Pubitemid 26052618)
17. Sapet C, Simoncini S, Loriod B, et al. Thrombin-induced endothelial microparticle generation: identification of a novel pathway involving ROCK-II activation by caspase-2. Blood. 2006; 108: 1868-1876. (Pubitemid 44394996)
18. Boulanger CM, Amabile N, Guerin AP, et al. In vivo shear stress determines circulating levels of endothelial microparticles in end-stage renal disease. Hypertension. 2007; 49: 902-908. (Pubitemid 351664206)
19. Kagawa H, Komiyama Y, Nakamura S, et al. Expression of functional tissue factor on small vesicles of lipopolysaccharide-stimulated human vascular endothelial cells. Thromb Res. 1998; 91: 297-304. (Pubitemid 28454727)
20. Nomura S, Shouzu A, Omoto S, et al. Activated platelets and oxidized LDL induce endothelial membrane vesiculation: clinical significance of endothelial cell derived microparticles in patients with type 2 diabetes. Clin Appl Thromb Hemost. 2004; 10: 205-215. (Pubitemid 38982044)
21. Pirro M, Schillaci G, Bagaglia F, et al. Microparticles derived from endothelial progenitor cells in patients at different cardiovascular risk. Atherosclerosis. 2008; 197: 757-767. (Pubitemid 351417873)
22. Chen J, Chen S, Chen Y, et al. Circulating endothelial progenitor cells and cellular membrane microparticles in db/db diabetic mouse: possible implications in cerebral ischemic damage. Am J Physiol Endocrinol Metab. 2011;301: E62-E71.
23. Rabelink TJ, de Boer HC, de Koning EJ, et al. Endothelial progenitor cells: more than an inflammatory response? Arterioscler Thromb Vasc Biol. 2004; 24: 834-838. (Pubitemid 38620859)
24. Kupatt C, Horstkotte J, Vlastos GA, et al. Endothelial progenitor cells are rapidly recruited to myocardium and mediate protective effect of ischemic preconditioning via "imported" nitric oxide synthase activity. Circulation. 2005; 111: 1114-1120.
25. Kupatt C, Horstkotte J, Vlastos GA, et al. Embryonic endothelial progenitor cells expressing a broad range of proangiogenic and remodeling factors enhance vascularization and tissue recovery in acute and chronic ischemia. FASEB J. 2005; 19: 1576-1578. (Pubitemid 41279036)
26. Pompilio G, Capogrossi MC, Cannata A, et al. Endothelial progenitor cells: a potential versatile tool for the treatment of ischemic cardiomyopathies-a clinician's point of view. Int J Cardiol. 2004; 95: S34-S37. (Pubitemid 39178507)
27. Zorn-Pauly K, Schaffer P, Pelzmann B, et al. Oxidized LDL induces ventricular myocyte damage and abnormal electrical activity-role of lipid hydroperoxides. Cardiovasc Res. 2005; 66: 74-83. (Pubitemid 40357870)
28. Senes M, Erbay AR, Yilmaz FM, et al. Coenzyme Q10 and high-sensitivity C-reactive protein in ischemic and idiopathic dilated cardiomyopathy. Clin Chem Lab Med. 2008; 46: 382-386. (Pubitemid 351320504)
29. Nomura S., Statin and endothelial cell-derived microparticles. Thromb Haemost. 2008; 100: 377-378.
30. Shishehbor MH, Patel T, Bhatt DL., Using statins to treat inflammation in acute coronary syndromes: Are we there yet? Cleve Clin J Med. 2006; 73: 760-766.
31. Okura H, Asawa K, Kubo T, et al. Impact of statin therapy on systemic inflammation, left ventricular systolic and diastolic function and prognosis in low risk ischemic heart disease patients without history of congestive heart failure. Intern Med. 2007; 46: 1337-1343. (Pubitemid 47455755)
32. Li MC, Liu JL., Effect of atorvastatin on cardiac function and plasma c-reactive protein and uric acid levels in patients ischemic cardiomyopathy. J Med Res. 2008; 37: 86-88.
33. LaRosa JC, Deedwania PC, Shepherd J, et al. Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial). Am J Cardiol. 2010;105: 283-287.
34. Tikkanen MJ, Szarek M, Fayyad R, et al. Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial. J Am Coll Cardiol. 2009;54: 2353-2357.
35. Johnson C, Waters DD, DeMicco DA, et al. Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study). Am J Cardiol. 2008; 102: 1312-1317.
36. LaRosa JC, Grundy SM, Kastelein JJ, et al. Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). Am J Cardiol. 2007; 100: 747-752. (Pubitemid 47271930)